Results of autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis
| Reference . | No. of patients . | Conditioning . | Comment . | Mortality . |
|---|---|---|---|---|
| Joske et al173 | 1 | Cy | Marked improvement at 6 mo follow-up | 0 |
| Snowden et al174 | 8 | Cy | Cohort I, cyclophosphamide 100 mg/kg-response for 1-2 mo | 0 |
| Cohort II, cyclophosphamide 200 mg/kg, improved for 17-19 mo | ||||
| Burt et al179 180 | 4 | Cy/ATG | Marked improvement up to 18 mo but 2 relapsed | 0 |
| Pavletic et al178 | 2 | Cy/ATG | Relapsed at 5 and 7 mo | 0 |
| Durez et al196 | 1 | BU/Cy | Remission > 10 mo | 0 |
| McColl et al175 | 1 | Cy/ATG (identical twin) | Remission > 24 mo | 0 |
| Munro et al278 | 1 | N/A | Marked improvement for 1 y | 0 |
| Verburg et al277 | 12 | Cy | Marked improvement in 8/12 patients with follow-up, ranging from 7-21 mo | 0 |
| Reference . | No. of patients . | Conditioning . | Comment . | Mortality . |
|---|---|---|---|---|
| Joske et al173 | 1 | Cy | Marked improvement at 6 mo follow-up | 0 |
| Snowden et al174 | 8 | Cy | Cohort I, cyclophosphamide 100 mg/kg-response for 1-2 mo | 0 |
| Cohort II, cyclophosphamide 200 mg/kg, improved for 17-19 mo | ||||
| Burt et al179 180 | 4 | Cy/ATG | Marked improvement up to 18 mo but 2 relapsed | 0 |
| Pavletic et al178 | 2 | Cy/ATG | Relapsed at 5 and 7 mo | 0 |
| Durez et al196 | 1 | BU/Cy | Remission > 10 mo | 0 |
| McColl et al175 | 1 | Cy/ATG (identical twin) | Remission > 24 mo | 0 |
| Munro et al278 | 1 | N/A | Marked improvement for 1 y | 0 |
| Verburg et al277 | 12 | Cy | Marked improvement in 8/12 patients with follow-up, ranging from 7-21 mo | 0 |
Cy indicates cyclophosphamide; Cy/ATG, cyclophosphamide and antithymocyte globulin; BU/Cy, busulfan and cyclophosphamide, and N/A, not applicable.